Phase 2 × Completed × Sarcoma × Clear all
NCT04191187 2025-12-11

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
34 enrolled 14 charts
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
NCT02988466 2025-05-28

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
78 enrolled 16 charts
NCT03213665 2025-01-27

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 12 charts
NCT03213678 2025-01-27

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
NCT03220035 2025-01-27

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
4 enrolled 12 charts
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts